Latest From Genmab AS
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.
German TCR developer in partnerships with GSK and BMS will go public and receive $252m at closing in a reverse merger-type transaction with Arya.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Genentech pays $30m up front in a collaboration with Bicycle in a deal that could bring the UK biotech roughly $1.7bn in total. Also, deals involving Nimble, Seattle Genetics, Five Prime, Fresenius, Vifor, Yuhan, Imnewrun, Paratek, Almirall, MBD, AzothBio, Norgine, Faes, Aspen Pharmacare, Swixx.
- Large Molecule
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Genmab AS
- Senior Management
Jan van de Winkel, PhD, Pres. & CEO
David A Eatwell, EVP, CFO
Judith Klimovsky, MD, EVP, Chief Dev. Officer
- Contact Info
Phone: (45) 7020 2728
Kalvebod Brygge 43
Copenhagen, 1560 V
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.